Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101–200 cells/µL in Botswana [version 2; peer review: 1 approved, 1 approved with reservations]

Mark W. Tenforde1-3, Charles Muthoga3,4, Ponego Ponatshego4, Julia Ngidi4,5, Madisa Mine5, Greg Greene6, Alexander Jordan6, Tom Chiller6, Bruce A. Larson7, Joseph N. Jarvis3,4,8

1Department of Medicine, University of Washington School of Medicine, Seattle, WA, 98195, USA
2Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, 98195, USA
3Botswana-UPenn Partnership, Gaborone, Botswana
4Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
5National Health Laboratory, Gaborone, Botswana
6Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA
7Department of Global Health, Boston University School of Medicine, Boston, MA, 02118, USA
8London School of Hygiene & Tropical Medicine, London, UK

Abstract
Background: Cryptococcal antigen (CrAg) screening in individuals with advanced HIV reduces cryptococcal meningitis (CM) cases and deaths. The World Health Organization recently recommended increasing screening thresholds from CD4 ≤100 cells/µL to ≤200 cells/µL. CrAg screening at CD4 ≤100 cells/µL is cost-effective; however, the cost-effectiveness of screening patients with CD4 101–200 cells/µL requires evaluation.

Methods: Using a decision analytic model with Botswana-specific cost and clinical estimates, we evaluated CrAg screening and treatment among individuals with CD4 counts of 101–200 cells/µL. We estimated the number of CM cases and deaths nationally and treatment costs without screening. For screening we modeled the number of CrAg tests performed, number of CrAg-positive patients identified, proportion started on pre-emptive fluconazole, CM cases and deaths. Screening and treatment costs were estimated and cost per death averted or disability-adjusted life year (DALY) saved compared with no screening.

Results: Without screening, we estimated 142 CM cases and 85 deaths annually among individuals with CD4 101–200 cells/µL, with treatment costs of $368,982. With CrAg screening, an estimated 33,036 CrAg tests are performed, and 48 deaths avoided (1,017 DALYs saved). While CrAg screening costs an additional $155,601, overall
treatment costs fall by $39,600 (preemptive and hospital-based CM
treatment), yielding a net increase of $116,001. Compared to no
screening, high coverage of CrAg screening and pre-emptive
treatment for CrAg-positive individuals in this population avoids one
death for $2440 and $114 per DALY saved. In sensitivity analyses
assuming a higher proportion of antiretroviral therapy (ART)-naive
patients (75% versus 15%), cost per death averted was $1472; $69 per
DALY saved.

**Conclusions:** CrAg screening for individuals with CD4 101–200 cells/µL
was estimated to have a modest impact, involve additional costs, and
be less cost-effective than screening populations with CD4 counts
≤100 cells/µL. Additional CrAg screening costs must be considered
against other health system priorities.

**Keywords**
Cryptococcal antigen, CrAg, fluconazole, pre-emptive treatment,
cryptococcal meningitis, HIV, AIDS, cost-effectiveness, modelling,
Botswana
Introduction

Botswana had an estimated adult HIV prevalence of over 20% in 2018, with approximately 350,000 adults living with HIV. This includes a sizable population with advanced HIV disease (CD4 ≤200 cells/µL) who are at an increased risk of opportunistic infections such as cryptococcal meningitis (CM). Reflex cryptococcal antigen (CrAg) screening with targeted fluconazole treatment for the prevention of CM was adopted in national HIV guidelines in 2016 at a CD4 T-cell count threshold of ≤100 cells/µL. We previously found screening at this threshold to be highly cost-effective (either cost-neutral or cost-saving across different model assumptions) and likely to prevent a significant proportion of CM cases and deaths.

In 2018, the World Health Organization (WHO) conditionally recommended increasing the CD4 count threshold for CrAg screening from ≤100 cells/µL to ≤200 cells/µL for the prevention of CM. Patients with CD4 counts of 101–200 cells/µL are also relatively immunocompromised and at risk for CM, but prevalence of CrAg positivity in this population, estimated at 2.0% (95% confidence interval (CI): 1.2-2.7%; 21 studies) is substantially lower than prevalence among patients with CD4 ≤100 cells/µL. The impact and cost-effectiveness of increasing the CrAg screening CD4 count threshold have not been systematically evaluated, and a better understanding of the potential impact (in terms of CM cases and deaths avoided), screening program resource needs, and cost effectiveness will inform countries as they consider changes to national screening guidelines.

Using data and estimates from Botswana in patients with a CD4 count of 101–200 cells/µL, the objective of this analysis is to expand our CrAg screening models to include those with a CD4 count of 101–200 cells/µL, with an aim of informing policy regarding CrAg screening for patients with higher CD4 counts. As in our previous analysis, we evaluated CrAg screening among patients who are antiretroviral therapy (ART)-naïve (those targeted for pre-emptive treatment in guidelines) as well as ART-experienced patients found to be CrAg-positive through reflex CrAg screening. This ART-experienced population re-engaging in care and treatment now makes up about half of those with incident CM in the region and are likely to derive clinical benefit from pre-emptive fluconazole treatment for the prevention of CM.

Methods

Overview

We used a decision analytic model to evaluate the number of patients receiving CD4 testing in Botswana who are at risk of cryptococcal meningitis and (1) develop CM without CrAg screening and (2) with national reflex CrAg screening adoption, as previously described, but in this analysis focused on those with a CD4 count of 101–200 cells/µL. The model estimates number of CM cases, CM-related deaths and disability-adjusted life years (DALYs) lost, and associated costs of CM management in the absence of screening (Figure 1A). This is compared with the estimated number of CM cases, CM-related deaths and DALYs lost, and associated costs of screening and pre-emptive therapy as well as costs of CM management for incident cases occurring despite implementation of screening (Figure 1B).

For these models, CD4 count distribution data were obtained from the Botswana-Harvard HIV Reference Laboratory, and local CrAg prevalence and titre data used to predict risk for progression to CM in the CD4 101–200 cells/µL population. Local data were obtained from a 2018–2019 CrAg screening cohort of patients with advanced HIV disease in Gaborone, which included over 900 patients with a CD4 count of 101–200 cells/µL who received reflex CrAg screening and were followed for up to 6 months for incident CM and mortality. In our model, based on local estimates we assume that 650,000 CD4 tests are performed annually for the adult HIV-positive population of 350,000 (around two tests per patient).

Screening module

The screening module (see Figure S1 in extended data), adapted from our previous model, estimates the proportion of patients who receive CD4 testing with a CD4 101–200 cells/µL, how many of these patients receive reflex CrAg screening, the proportion who are CrAg-positive, and the proportion previously initiated on ART, i.e. “ART-experienced” (see Figure S1 in extended data and key parameter assumptions in Table 1). From country data, 5.35% of all CD4 tests performed in greater Gaborone have a CD4 T-cell count between 101 and 200 cells/µL (Table 1). Only a small proportion (15%) of patients with a CD4 101–200 cells/µL were ART-naïve in 2018–2019. Patients were considered ART-experienced if they had a prior history of HIV viral load testing documented in the national electronic medical record, as viral load testing is exclusively performed after initiation of ART as per national guidelines. In the absence of prior documented viral load testing, a patient was assumed to be ART-naïve.

Based on data from the prospective 2018–2019 CrAg screening cohort, among screened outpatients in the 101–200 cells/µL...
CD4 T-cell count range, CrAg prevalence was estimated at 3.1%, 35% of whom had a history of treated CM; thus 2.0% of screened outpatients with a CD4 count of 101–200 cells/µL are estimated to be incident CrAg positives (no history of prior CM) and the target population for pre-emptive fluconazole treatment.

We used serum CrAg titre data to stratify the risk of CrAg-positive patients progressing to CM\(^1\), with a titre >1:160 corresponding with a high risk for incident cryptococcal disease. Approximately 20% of CrAg-positive outpatients with a CD4 101–200 cells/µL had a high CrAg titre, compared to 59% among those with lower CD4 counts of ≤100 cells/µL\(^2\). For our CD4 101–200 cells/µL models, we assume that patients who screen CrAg-positive and return to clinic are started on pre-emptive fluconazole therapy and none receive a diagnostic lumbar puncture to evaluate for central nervous system infection, given the lower distribution of CrAg titres in the CD4 101–200 cells/µL population compared to ≤100 cells/µL and frequent lumbar puncture refusal in routine-care settings\(^3\).

Our base model assumes that 5% of patients with CD4 101–200 cells/µL do not receive CrAg screening due to laboratory error or assay stockout and that 10% of patients who screen CrAg-positive do not return to clinic to begin pre-emptive fluconazole, putting them at higher risk for progression to CM.

**Base model: CrAg screening at CD4 101–200 cells/µL, treatment for both ART-naïve and ART-experienced**

The base model treatment module (see Figure S2 in extended data\(^4\) and key parameter assumptions in Table 1) includes outcomes for patients (1) with a CD4 count of 101–200 cells/µL who do not receive CrAg screening, (2) who are screened and CrAg-positive but do not subsequently initiate fluconazole therapy, and (3) who are screened and started on pre-emptive fluconazole therapy.

Full modeling assumptions are detailed in a Microsoft Excel file accessible online\(^5\). Risk of progression to CM is dictated by whether a patient has a high- (>1:160) or low (≤1:160) CrAg titre\(^6\). For patients who either don’t receive CrAg screening or receive screening but do not subsequently initiate fluconazole therapy, given the comparatively lower CrAg titre distribution in patients with higher CD4 counts of 101–200 cells/µL, we expect a longer delay until progression to CM in the absence of pre-emptive fluconazole compared to CrAg-positive patients with CD4 cell counts ≤100 cells/µL (Figure S1 in extended data\(^7\)). However, initiation of fluconazole therapy in CrAg-positive patients further reduces the risk of progression to CM in the population with CD4 101-200 cells/µL.

Outcomes of patients who develop incident CM are informed by local mortality data from Botswana, with approximately...
50% of patients dying within 10 weeks of CM diagnosis under routine care conditions\textsuperscript{9,17}. Patients who are recognized as CrAg-positive and started on pre-emptive fluconazole but subsequently fail therapy and are admitted to the hospital for the management of CM are assumed to have better clinical outcomes (25% versus 50% 10-week mortality) based on limited data from South Africa\textsuperscript{14}. Some patients who develop CM and survive hospitalization may develop relapsed CM. Given the small proportion of these patients and small clinical and public health impact, we do not consider them further in our models.

With reflex CrAg screening, patients receive CrAg screening based on CD4 count regardless of prior ART status. However, most (85%) patients with a CD4 count of 101–200 cells/µL are now ART-experienced according to recent cohort data from Botswana 2018–2019\textsuperscript{12}. Very little outcome data exist in this disparate sub-population, which consists of patients: (1) recently started on ART; (2) ART-experienced who defaulted and are now re-establishing care; and (3) ART-experienced but with treatment failure. From local 2018–2019 cohort data in Botswana, approximately 75% of these ART-experienced patients are considered to have recently started on ART (with an undetectable HIV viral load in the previous three months), 20% are on ART but with a recent unsuppressed HIV viral load signifying treatment failure, and 5% have a history of recent ART use without a recent HIV viral load signifying likely ART default\textsuperscript{18}. For those recently started on ART, we assumed a 33% reduction in risk of CM for those with CD4 \(101–200\) cells/µL compared to our previous estimates for those with CD4 \(\leq 100\) cells/µL. In our base model, based on prospective cohort data\textsuperscript{13}, those recently started on ART with a suppressed HIV viral load have a low risk of progression to CM without pre-emptive fluconazole therapy (7%), with a

<table>
<thead>
<tr>
<th>Table 1. Key parameters, estimates, and sources of data for base model.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Screening Module</strong></td>
</tr>
<tr>
<td>% within CD4 strata</td>
</tr>
<tr>
<td>CrAg prevalence within CD4 strata (outpatient), %</td>
</tr>
<tr>
<td><strong>Among CrAg-positive individuals:</strong></td>
</tr>
<tr>
<td>Proportion with prior CM, %</td>
</tr>
<tr>
<td>Proportion with CrAg titre (\geq 1:160), %</td>
</tr>
<tr>
<td>Proportion ART-naïve, %</td>
</tr>
<tr>
<td>Return to clinic for pre-emptive treatment, %</td>
</tr>
<tr>
<td><strong>Treatment Module</strong></td>
</tr>
<tr>
<td>Hospitalized if missed CrAg+ and develops CM, %</td>
</tr>
<tr>
<td>10-week CM mortality</td>
</tr>
<tr>
<td>CM relapse</td>
</tr>
<tr>
<td>Fail pre-emptive therapy (if receive fluconazole) - High CrAg titre, ART-naïve*</td>
</tr>
<tr>
<td>Fail pre-emptive therapy (if receive fluconazole) - Low CrAg titre ART-naïve*</td>
</tr>
<tr>
<td>Hospitalized if fail pre-emptive therapy and develop CM</td>
</tr>
<tr>
<td>10-week mortality</td>
</tr>
<tr>
<td>CM relapse</td>
</tr>
<tr>
<td>Hospitalized if diagnosed with CM at urgent follow-up visit</td>
</tr>
<tr>
<td>10-week mortality</td>
</tr>
<tr>
<td>CM relapse</td>
</tr>
</tbody>
</table>

ART = antiretroviral therapy; BHHRL = Botswana-Harvard HIV Reference Laboratory; CrAg = cryptococcal antigen; CM = cryptococcal meningitis

* Assumptions about failed pre-emptive therapy for ART-experienced as included in extended data and underlying data\textsuperscript{13}.
greater risk in those with ART treatment failure (60%) and ART defaulters (33%). The combined risk of progression to CM for all ART-experienced patients in the CD4 101–200 cells/µL group is assumed to be 19% without pre-emptive treatment. We estimate an 87.5% reduction in risk of incident CM with pre-emptive fluconazole (factoring in a relatively low baseline CrAg titre distribution in this group)\textsuperscript{19}.

**CrAg screening and treatment unit costs**

Costing data for CrAg screening, pre-emptive therapy, and CM treatment costs are derived using local costing data when available (Table 2 and underlying data\textsuperscript{13}). Patients who screen CrAg-positive and receive pre-emptive fluconazole are treated with fluconazole 1200 mg/day for 2 weeks, followed by 800 mg/day for 8 weeks, then 200 mg/day maintenance fluconazole for an average duration of six months pending CD4 count recovery. For patients who progress to CM, hospital bed-day costs, factoring length of hospital admission\textsuperscript{9}, were derived using WHO-CHOICE estimates\textsuperscript{20–22}. CM treatment costs are based on two inpatient weeks of amphotericin B deoxycholate with high-dose fluconazole, intravenous fluid and electrolyte supplementation, and laboratory monitoring, followed by consolidation and maintenance fluconazole, as recommended in national treatment guidelines\textsuperscript{3}.

**Outcomes**

Our model estimates the number of CM cases and CM-related deaths nationally in the population with a CD4 101–200 cells/µL without CrAg-screening and pre-emptive fluconazole therapy along with treatment costs for CM management. With implementation of CrAg screening, we then model the number of CM cases and CM-related deaths prevented in the base model (with pre-emptive fluconazole for all CrAg-positive patients) along with associated costs for screening, pre-emptive fluconazole therapy, and CM treatment. We estimate the cost per death averted and cost per DALY saved compared to no screening, assuming an average age of death of 36 years\textsuperscript{9}. With a 3% annual discount rate and age-specific life expectancy from WHO Global Health Observatory, 21.4 DALYs are saved per avoided death\textsuperscript{23}.

### Table 2. Included cost estimates for CrAg screening and pre-emptive treatment and for cryptococcal meningitis treatment.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Estimate (USD)</th>
<th>Source(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CrAg screening and pre-emptive therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CrAg LFA</td>
<td>$4.71</td>
<td>IMMY wholesale plus additional costs</td>
</tr>
<tr>
<td>Pre-emptive fluconazole 1200 mg/day x2 weeks 800 mg/day x8 weeks 200 mg/day x26 weeks</td>
<td>$0.51 / 200 mg tablet x 490 tablets = $247.54</td>
<td>CMS; proportion with treatment failure or partial adherence</td>
</tr>
<tr>
<td>Extra visit</td>
<td>$9.43</td>
<td>Assumption</td>
</tr>
<tr>
<td><strong>Treatment Module</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital costs 17-day hospital stay</td>
<td>$188.51 / hospital day</td>
<td>9,20</td>
</tr>
<tr>
<td>Hospital drug and procedure costs Including 14 days AmBd and FLU, 2 lumbar punctures</td>
<td>$202.24 (survives), $151.68 (dies)</td>
<td>CMS;\textsuperscript{9}</td>
</tr>
<tr>
<td>Post-admission costs FLU consolidation/maintenance, Extra clinic visit</td>
<td>$226.37</td>
<td>CMS</td>
</tr>
<tr>
<td>Laboratory costs 2 FBC, 4 U/E, 1 ALT</td>
<td>$71.00</td>
<td>BHHRL; WHO guideline\textsuperscript{5}</td>
</tr>
</tbody>
</table>

\textsuperscript{*} Underlying data includes detailed costing estimates\textsuperscript{13}
ALT = alanine aminotransferase; AmBd = amphotericin B deoxycholate; BHHRL = Botswana Harvard HIV Reference Laboratory; CM = cryptococcal meningitis; CMS = Central Medical Stores; FBC = full blood count; FLU = fluconazole; KCl = potassium choloride; Mg = magnesium supplementation; NS = normal saline; U/E = urea and electrolyte testing; WHO = World Health Organization
Sensitivity analyses
Three main sensitivity analyses are reported to account for key areas of parameter uncertainty. The complete Excel-based model is provided as underlying data so that alternative sensitivity analyses can be completed by interested readers.

Sensitivity analysis 1 (SA1): In this analysis, we assume that in some real world settings a lower proportion of CrAg-positive patients are started on pre-emptive fluconazole after laboratory testing (50% versus 90% in the base model) because of programmatic barriers such as inadequate communication of test results to clinics, a lack of fluconazole availability in clinics, lack of provider awareness of treatment guidelines, or for other reasons. This analysis still assumes that 90% of patients attended in outpatient clinics and receiving CD4 testing will stay engaged in health care. Other parameters remain the same as the base model.

Sensitivity analysis 2 (SA2): In this model, we assume less benefit of pre-emptive fluconazole in CrAg-positive patients, with a 75% rather than 87.5% reduction in incident CM. This is to account for significant uncertainty in the benefits of pre-emptive fluconazole in this population with a higher CD4 count, and for possible sub-optimal adherence to therapy. Other parameters remain the same as the base model.

Sensitivity analysis 3 (SA3): In this model, we test our parameters with a higher proportion of ART-naïve patients receiving CD4 testing and CrAg screening (75% versus 15% in the base model). Other parameters remain the same as the base model. This is to provide estimates applicable to settings with less mature ART programmes where a higher proportion of individuals with CD4 counts of 101–200 cells/µL are likely to be ART-naïve.

Sensitivity analysis 4 (SA4): In this model, we expand model 3 which assumes a greater ART-naïve population than observed in Botswana. We also consider lower costs of CM care in other settings. Based on a costing analysis from a cryptococcal meningitis clinical trial that enrolled patients from four countries in sub-Saharan Africa, we use a reduced cost of $2125.00 for two weeks of hospitalization with amphotericin B and fluconazole therapy for incident CM. This model also includes a lower cost of fluconazole therapy used for either CM treatment or targeted preventive treatment for CrAg-positive patients. As in the base model, here we assume a lower cost of care in patients who die during hospitalization (75%). Other costs remain unchanged compared to the base model.

Results
Cryptococcal meningitis cases and costs without screening
Without CrAg screening (Table 3), we estimate 142 annual cases of incident CM in Botswana among those with a CD4 test result 101–200 cells/µL. Unlike in our prior analysis of screening in the CD4 ≤100 cells/µL sub-population, most of these incident CM cases (113 of 142, 79%) are in ART-experienced patients4. Of patients with incident CM, 60% (85/142) are estimated to die (including those diagnosed and managed in hospital and those who die outside of the hospital without a confirmed diagnosis). The total estimated CM treatment costs are $368,982 annually for the health care system.

| Table 3. Cryptococcal meningitis outcomes and costs of treatment without CrAg screening.* |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Population: CD4 101-200 cells/µL | Results - ART-naïve | Results - ART- experienced | Total |
| | Number patients | Cost for patients (USD) | Number patients | Cost for patients (USD) |
| Identified for preemptive treatment (but did not receive), but did not develop CM – survives | 0.0 | 0 | 0.0 | 0 |
| Identified for preemptive treatment, receives treatment, survives | 0.0 | 0 | 0.0 | 0 |
| Not hospitalized, dies | 5.8 | 0 | 22.5 | 0 |
| Hospitalized, dies < 10 weeks | 11.6 | 31,870 | 45.0 | 123,939 |
| Hospital, survives maintenance | 9.6 | 36,191 | 37.4 | 140,742 |
| Hospital, CM relapse | 2.0 | 7,413 | 7.7 | 28,827 |
| Total Treatment Costs | 75,474 | 293,508 | 368,982 |
| Total Screening Costs (reflex policy) | 0 | 0 | 0 |
| Total Costs | 75,474 | 293,508 | 368,982 |
| Total Cases of CM | 28.9 | 112.6 | 142 |
| Total Deaths from CM | 17.4 | 67.5 | 85 |

ART = antiretroviral therapy; CrAg = cryptococcal antigen; CM = cryptococcal meningitis
* Models assumes 650,000 CD4 T-cell count tests performed annually in Botswana
Base model: CrAg screening at CD4 101–200 cells/µL, treatment for both ART-naïve and ART-experienced

With implementation of reflex CrAg screening (Table 4), 33,036 CrAg tests are performed at a cost of $155,601. Pre-emptive treatment averted 48 deaths compared to no screening (1,017 DALYs saved). While CrAg screening costs an additional $155,601 compared to no screening, treatment costs fall by $39,600 (preemptive treatment plus hospital-based CM treatment), for a net increase of $116,001 (Table 5). Compared to no screening, high coverage of CrAg screening and pre-emptive treatment for CrAg-positive individuals in this population is associated with a cost of $2440 per one death averted or $114 per DALY saved (Table 5).

Sensitivity analyses
SA1 and SA2 assume a lower proportion of CrAg positive are started on pre-emptive fluconazole and a reduced benefit of pre-emptive fluconazole therapy for CrAg-positive patients with a CD4 101–200 cells/µL, respectively, which may be more realistic under many routine care conditions. Both models will therefore result in a smaller public health benefit to CrAg screening and a higher incremental cost per death or DALY saved. For SA1, an estimated 25% (21/85) of deaths are averted with treatment of both ART-naïve and ART-experienced with a cost per death averted of $7476 or $349 per DALY saved (Figure 2). For SA2, 52% (44/85) of deaths are averted with treatment of ART-naïve and experienced at a cost per death

<table>
<thead>
<tr>
<th>Table 4. Outcomes with CrAg screening and pre-emptive fluconazole for ART-naïve and ART-experienced (base model).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population: CD4 101–200 cells/µL</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Identified for preemptive treatment (but did not receive), but did not develop CM - survives</td>
</tr>
<tr>
<td>Identified for preemptive treatment, receives treatment, survives</td>
</tr>
<tr>
<td>Not hospitalized, dies</td>
</tr>
<tr>
<td>Hospitalized, dies &lt;10 weeks</td>
</tr>
<tr>
<td>Hospital, survives maintenance</td>
</tr>
<tr>
<td>Hospital, CM relapse</td>
</tr>
<tr>
<td><strong>Total Treatment Costs</strong></td>
</tr>
<tr>
<td><strong>Total Screening Costs (reflex policy)</strong></td>
</tr>
<tr>
<td><strong>Total Costs</strong></td>
</tr>
<tr>
<td><strong>Total Cases of CM</strong></td>
</tr>
<tr>
<td><strong>Total Deaths from CM</strong></td>
</tr>
</tbody>
</table>

ART = antiretroviral therapy; CrAg = cryptococcal antigen; CM = cryptococcal meningitis
* Models assumes 650,000 CD4 T-cell count tests performed annually in Botswana

<table>
<thead>
<tr>
<th>Table 5. Summary of costs and outcomes for no screening and screening plus pre-emptive treatment.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population: CD4 101–200 cells/µL</strong></td>
</tr>
<tr>
<td><strong>No screening</strong></td>
</tr>
<tr>
<td><strong>Base model: Screening 101–200, preemptive treatment to both ART-naïve and ART-experienced</strong></td>
</tr>
</tbody>
</table>

ART = antiretroviral therapy; CrAg = cryptococcal antigen; CM = cryptococcal meningitis; DALY = disability-adjusted life year
* Models assumes 650,000 CD4 T-cell count tests performed annually in Botswana
averted of $3360 or $157 per DALY saved. For SA3, assuming a higher proportion of ART-naïve patients are among the screened population (75% versus 15%) results in slightly enhanced public health benefit and cost per death or DALY saved as the base model (see Excel file with underlying data13), with an estimated 56% (60/107) reduction in CM-related deaths at a cost of $1472 per death averted and $69 per DALY saved. For SA4, the number of deaths averted and DALY saved is equivalent to SA3. The lower cost of hospital management of incident CM is offset by the lower cost of fluconazole pre-emptive treatment in this model, with an overall similar cost of $1132 per death averted and $53 per DALY saved.

Overall estimated costs, number of CM cases, number of deaths averted, and DALYs saved for the base model and sensitivity analyses are summarized in Figure 3.

Discussion

We used local data from Botswana to estimate the cost and impact of laboratory-based CrAg screening for HIV-positive patients with CD4 counts 101–200 cells/µL across a range of assumptions. Compared to screening in patients with very advanced HIV disease (CD4 ≤100)4, the benefit of screening for those with higher CD4 counts, in terms of avoided CM cases and deaths, is less marked. Under base model assumptions compared to no screening for this higher CD4 category of patients, 48 deaths are averted and screening costs of about $156,000 are offset by a $40,000 reduction in treatment costs (mainly CM-based hospital care and treatment). The cost per death averted through CrAg screening and pre-emptive fluconazole therapy was estimated at about $2400 ($114 per DALY avoided). If substantially fewer patients who screen CrAg-positive are started on pre-emptive fluconazole therapy (50% compared to 90% in the base case analysis), which might better reflect some real-world conditions without focused efforts on providing preemptive treatment, the estimated cost per death averted increases to over $7000 (and $349 per DALY saved).

Compared to prior analyses of CrAg screening for patients with CD4 ≤100 cells/µL, fewer CrAg positive patients with CD4 101–200 cells/µL are likely to have high CrAg titres (~20% in the higher CD4 group compared to ~60% in the lower CD4 group12,13), which reduces the risk of incident CM and failure of pre-emptive fluconazole14. In addition, overall CrAg prevalence among the CD4 101–200 cells/µL group is estimated to be less than the CD4 ≤100 cells/µL group. Both of these factors reduce the benefit of screening among patients with higher CD4 counts.

As of 2021, Botswana has an advanced ART program. Whereas CrAg screening guidelines have primarily focused on ART-naïve patients5, a large majority of patients with advanced HIV disease in Botswana are ART-experienced. From recent data of 2018–2019, we found that most outpatients receiving CD4 testing in the greater Gaborone region with a CD4 count of 101–200 cells/µL were currently on ART12. We included a sensitivity analysis assuming that a majority (75%) of patients who received CD4 testing and CrAg screening were
ART-naïve, which may inform other health systems with a higher proportion of ART-naïve patients receiving CrAg screening with ART initiation. This sensitivity analysis showed a slightly better impact and cost-effectiveness compared to the base model assuming most patients were ART-experienced although screening was still not cost-neutral or cost-saving.

This study is subject to a number of limitations. First, we used local clinical and costing estimates. The relative costs of CrAg screening, pre-emptive fluconazole therapy, and CM treatment between different health systems may impact cost-effectiveness of CrAg screening between settings. We therefore performed sensitivity analysis considering other published estimates of CM management and fluconazole costs in sub-Saharan Africa. Secondly, the base model presents optimistic management assumptions, with about 90% of CrAg-positive patients started on pre-emptive therapy and a nearly 90% reduction in incident CM assuming relatively good adherence. Sensitivity analyses showed that under less ideal assumptions the cost per death averted or DALY saved could increase substantially. Notably,
under no model assumptions was CrAg screening in this population estimated to be cost-neutral or cost-saving. Third, there is considerable uncertainty in model estimates, particularly regarding the clinical benefit of pre-emptive therapy in ART-experienced patients. Fourth, we used local CD4 testing practices in Botswana to inform these estimates. Alternative testing practices, such as testing only ART-experienced patients who have treatment failure based on HIV viral load testing or who are newly engaging in care following default, may result in greater cost-effectiveness of reflex CrAg testing.

In summary, nationwide CrAg screening in patients with advanced HIV disease with a CD4 count of 101–200 cells/µL in Botswana is estimated to have a modest impact (48 deaths avoided annually) for a modest additional cost to the overall HIV/AIDS care and treatment program ($116,000), with a relatively low cost per DALY saved ($114 base case). With less coverage of pre-emptive treatment for CrAg positive patients, the cost per DALY saved, compared to no screening, is estimated at about $350. Overall, expanding screening to this higher CD4 count population would be estimated to require about 33,000 additional CrAg tests annually, with an estimated cost of about $156,000. These models do not make assumptions about government willingness to pay thresholds. While the Government of Botswana is the ultimate decision maker for the public provision of health care, our results suggest that CrAg screening is cost effective based on a wide range of parameter assumptions, according to published thresholds10,13. With current public spending on HIV care of approximately $103 million15, added costs from screening under base model assumptions ($116,001) could contribute marginally to governmental spending in HIV services (~0.1%). The decision of whether or not to adopt CrAg screening in national HIV advanced disease guidelines among patients with higher CD4 counts (101–200 cells/µL) will rely on the availability of these additional resources and competing health system priorities.

**Data availability**

**Underlying data**


This project contains the following underlying data:

- CD4 100–200 full model data.xlsx
- CD4 101-200 full model data_27nov21.xlsx

**Extended data**


This project contains the following extended data:
- Figures S1 (flowchart of screening module) and S2 (flowchart of treatment module)

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

**References**


**Reference Source**


**Reference Source**


Open Peer Review

Current Peer Review Status: ✔️ ?

Version 1

Reviewer Report 22 September 2021

https://doi.org/10.21956/wellcomeopenres.18328.r45594

© 2021 Popping S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stephanie Popping
1 Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands
2 Department of Medical Microbiology and Infectious Disease, Erasmus MC, Rotterdam, The Netherlands

This research describes a decision based model to analyse the cost-effectiveness of cryptococcal antigen screening among people living with HIV with an CD4 cell-count between 101-200 cells.

The authors use a previously published adapted model of which all the data is online available. The performed sensitivity analyses for several uncertainties in their data. It is an interesting topic as the WHO changed the CD4 threshold for cryptococcal screening.

I have some minor comments/considerations:
  - It is unclear from the methods how much simulations are run in the model
  - Table 2 says "hotel costs" I think this should be hospital
  - What is the willingness to pay threshold in Botswana. It is hard to make the conclusion whether screening people with a CD4 cell count between 101-200 is cost-effective or even cost-saving if someone is not familiar with the numbers. Maybe also add the total HIV/AIDS care and treatment program budget just to place the amount in perspective
  - Limitation 1 of the study can be addressed by changing this in a sensitivity analysis. That would make the work more useful for other countries too

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?  
Yes

If applicable, is the statistical analysis and its interpretation appropriate?  
Yes

Are all the source data underlying the results available to ensure full reproducibility?  
Yes

Are the conclusions drawn adequately supported by the results?  
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: medical microbiology, virology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
viral load (VL) test is used as the proxy for ART experience, it would be good to know if all these VL tests are done after 6 months of ART or at what time point this is done. Pragmatically with all logistical challenges in resource limited settings, a recommendation to do a six month viral load will mean the viral load was done at about month eight or nine after ART start. Wondering if this choice of defining ART experience could have lumped many ART experience persons as non experienced.

Page 3, the last paragraph talks about the assumptions for those who did not receive CrAG screening, however it’s not clear where these estimates are derived from. Is this lab data or data from the prospective cohort. Also it seems to belong under the next subheading and yet has been placed under the screening model.

The base model, the cost analysis and the sensitivity analysis are presented well and in detail and are supplemented by the tables giving a clear picture of what was being done. The discussion of study findings is comprehensive and puts them in context and the conclusions have been derived systematically from the data presented.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
I cannot comment. A qualified statistician is required.

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Cryptococcal meningitis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Comments on this article**
Below are author response to reviewers. We thank the reviewers for their careful review and thoughtful feedback.

Reviewer #1

The study title is short and smart and gives a glimpse into what the paper is about. The study is well introduced however I would reorganize the paragraphs to get a better flow, that is: The first sentence of paragraph two can be moved to the beginning of the introduction to draw the picture on how big the HIV problem is in Botswana upfront and then talk about the rationale after. I would merge and reorganize the first two paragraphs.

Author response: We thank Dr. Nalintya for this overall positive and constructive feedback and agree that the introduction could benefit from re-organization. We have modified paragraphs 1 and 2 to first discuss the HIV-related country context in Botswana and current evidence for CrAg screening at CD4 counts of £100 cells/µL before discussing modified WHO guidelines to expand CrAg screening to higher CD4 counts and the study objective of evaluating CrAg screening in Botswana at higher CD4 counts now recommended in international guidelines.

In the methods section, a great deal of work has gone into explaining how the different estimates were arrived at and what type of data was used to arrive at the estimates. This however blurs the description of the actual modeling. It would be beneficial to the reader to get a quick snap short of the final model (could be in a summarized figure placed within the text explaining the methods) This is especially because the figure S1 is very busy and can get confusing, the reader needs to understand what the final model is before trying to understand the smaller details of how the model was arrived at.

Author response: We thank the reviewer for this suggestion. We have added a summary Figure 1 to broadly describe the model as an orientation and added some overview discussion at the beginning of methods. We agree that Figure S1 is very busy, and thus was moved to the supplementary materials.

The screening model clearly talks about the estimates included and how they are arrived at. The viral load(VL) test is used as the proxy for ART experience, it would be good to know if all these VL tests are done after 6 months of ART or at what time point this is done. Pragmatically with all logistical challenges in resource limited settings, a recommendation to do a six month viral load will mean the viral load was done at about month eight or nine after ART start. Wondering if this choice of defining ART experience could have lumped many ART experience persons as non-experienced.

Author response: Thank you for this point. According to national guidelines, for patients on first therapy viral load monitoring is recommended at 3 months, 6 months if not suppressed, and at 12 months, and twice-yearly thereafter. Patients on second line regimens have more frequent CD4 count monitoring recommended. We agree that it is possible for patients to not be captured as on ART if viral load testing is not performed regularly, but ART clinics generally adhere to routine viral load testing in patients with
regular follow-up and hence - in the absence of detailed medication records - made these assumptions about ART status based on viral load testing in the model.

Page 3, the last paragraph talks about the assumptions for those who did not receive CrAG screening, however it's not clear where these estimates are derived from. Is this lab data or data from the prospective cohort. Also it seems to belong under the next subheading and yet has been placed under the screening model.

*Author response: We agree that this discussion of risk of incident CM in patients who have a CD4 count of 101-200 cells/µL but do not receive CrAg screening is more appropriate in the section below. These are considered best estimates informed by relative CrAg titre distribution within CrAg-positive populations within differing CD4 strata, which hopefully is clearer.*

The base model, the cost analysis and the sensitivity analysis are presented well and in detail and are supplemented by the tables giving a clear picture of what was being done. The discussion of study findings is comprehensive and puts them in context and the conclusions have been derived systematically from the data presented.

*Author response: Thank you again for this positive and constructive feedback which we have incorporated to improve the manuscript.*

**Reviewer #2**

This research describes a decision based model to analyse the cost-effectiveness of cryptococcal antigen screening among people living with HIV with a CD4 cell-count between 101-200 cells.

The authors use a previously published adapted model of which all the data is online available. The performed sensitivity analyses for several uncertainties in their data. It is an interesting topic as the WHO changed the CD4 threshold for cryptococcal screening.

I have some minor comments/considerations:

It is unclear from the methods how much simulations are run in the model

*Author response: Thank you to Dr. Popping for the thorough review and constructive feedback. These models were simple decision analytic models using proportions without simulations performed. Based on areas of uncertainty, such as reduction in risk of incident cryptococcal meningitis with pre-emptive fluconazole in patients with CD4 counts of 101-200 cells/µL, or more generalized public health considerations, such as proportion of screened patients who are ART-experienced, we ran a number of sensitivity analyses to evaluate findings across varying assumptions.***

Table 2 says “hotel costs” I think this should be hospital

*Author response: Thank you, we have modified the wording for clarity to state “hospital” costs. We were using “hotel” as a general term for facility-related costs (Jarvis et al PLoS One 2013), but hospital is more interpretable.*
What is the willingness to pay threshold in Botswana. It is hard to make the conclusion whether screening people with a CD4 cellcount between 101-200 is cost-effective or even cost-saving if someone is not familiar with the numbers. Maybe also add the total HIV/AIDS care and treatment program budget just to place the amount in perspective

**Author response: Thank you for this important point.** While our estimated costs per DALY averted are substantially lower than GDP-based thresholds often used in the past (e.g., > $6,000 per year in Botswana -- [https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=BW](https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=BW)), such thresholds are no longer considered particularly useful by many (Bertram et al., 2016; Leech, Kim, Cohen, & Neumann, 2018; Marseille, Larson, Kazi, Kahn, & Rosen, 2015). Instead of focusing on "demand-side" thresholds and government willingness to pay, other research has focused on typical costs of producing health outcomes, in this case DALYs averted, as a reference point for cost-effectiveness thresholds. For example, based on a range of methodological details, Ochalek et al. 2015 estimate a DALY-based threshold for Botswana in the $365-660 range (see Table 9) (Ochalek, Lomas, & Claxton, 2015). While the Government of Botswana is the ultimate decision maker for the public provision of health care, our results suggest that CrAg screening is cost effective based on a wide range of parameter assumptions. We have added these points to the last paragraph of the Discussion, as well as estimated overall treatment costs of HIV care in Botswana. Using public funding estimates for HIV care in Botswana, CrAg screening among individuals with a CD4 count of 101-200 cells/µL is estimated to account for ~0.1% of public costs.

**Refs:**


Limitation 1 of the study can be addressed by changing this in a sensitivity analysis. That would make the work more useful for other countries too

**Author response: Thank you for raising this important consideration and we also hope that findings from this analysis will be relevant in other settings.** We agree that we could go a step further in the sensitivity analyses to potentially make these findings more broadly relevant for other ART programs who: 1) may have a higher proportion of ART-naive with low CD4 counts (as addressed in sensitivity analysis #3); and 2) may have lower costs of drugs or other care than Botswana (an upper middle income country).

For this sensitivity analysis 4, we considered modifying costs of hospital-based care for cryptococcal meningitis as well as costs of drugs, namely fluconazole pre-emptive treatment for CrAg-positive. Hospital costs including facility costs per day were based in part on WHO-CHOICE estimates due to lack of more detailed local estimates of hospital costs in Botswana. Investigators from a large randomized
controlled trial of cryptococcal meningitis induction treatments (the ACTA trial) conducted in 4 countries in Africa (Cameroon, Malawi, Tanzania, and Zambia) published detailed costing estimates of US$2125 for 2 weeks of hospitalization with amphotericin B and fluconazole treatment (Chen et al Clin Infect Dis 2019). For our analysis, we assumed a 17-day hospital stay with overall in-hospital treatments approximately US$3500. Costs per 1200 mg of fluconazole was US$0.55 in this published costing analysis, substantially lower than costs in Botswana by approximately 6-fold.

For sensitivity analysis 4, using other estimates of cost of cryptococcal meningitis hospitalization and fluconazole therapy used for both CrAg-positive and patients treated for cryptococcal meningitis, we have re-run the model assuming a price of hospitalization of US$2125 (including 75% cost in patients who die), a cost of fluconazole of US$0.10 / 200 mg tablet, and additional costs of post-hospitalization maintenance therapy based on this lower fluconazole cost. Other costs remain the same. As in sensitivity analysis #3, here we again assume that 75% of patients are ART-naïve in less mature ART programs than Botswana.

In this analysis, the lower cost of fluconazole treatment for CrAg-positive patients is offset by the lower cost of hospitalization in patients hospitalized with incident cryptococcal meningitis. The impact of screening and costs per death and DALY averted therefore remain similar to sensitivity analysis 3. We included further mention of these findings in the results and discussion.

**Competing Interests:** The authors have no competing interests to disclose.